HALOZYME THERAPEUTICS, INC. (HALO) Income statement

Market cap

$7.9B

P/E ratio

	2011/12	2012/12	2013/12	2014/12	2015/12	2016/12	2017/12	2018/12	2019/12	2020/12	2021/12	2022/12	2023/12	2024/12
Revenue	56	42	55	75	135	147	317	152	196	268	443	660	829	1,015
Revenue growth (%)	-
Cost of revenue	257,834	1	6	23	29	33	31	10	46	43	81	139	192	159
Research & development	58	70	97	80	93	151	151	150	141	34	36	67	76	79
Selling, general & administrative	18	25	32	36	40	46	54	61	77	46	50	144	149	154
Operating margin (%)
Operating expenses	76	96	135	138	163	230	236	221	264	123	167	393	492	464
Operating income	-19,838,941	-53,625,446	-80,433,637	-63	-27	-83	81	-69	-68	144	276	268	338	551
Income before tax	-	-	-	-	-	-102	62	-80	-72	129	249	249	348	557
Pretax margin (%)	-	-	-	-	-	-69.4	19.5	-52.5	-36.9	48.3	56.1	37.7	42	54.9
Provision for income taxes	-	-	-	-	-	1	-1	1	-0	0	-154	47	67	113
Effective tax rate (%)	-	-	-	-	-
Net income	-19,769,851	-53,552,002	-83,478,551	-68	-32	-103	63	-80	-72	129	403	202	282	444
Net income margin (%)
Earnings per share	-	-	-	-	-	-	0.46	-0.56	-	0.95	2.86	1.48	2.13	3.5
Diluted EPS	-	-	-	-	-	-	0.45	-0.56	-0.5	0.91	2.74	1.44	2.1	3.43
EBITDA
EBITDA margin (%)